Wealth Enhancement Advisory Services’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-12,095
Closed -$16.1K – 4267
2026
Q2
$16.1K Buy
+12,095
New +$19.2K ﹤0.01% 4060

Other funds holding CRDF

Wealth Enhancement Advisory Services's CRDF Position: Q3 2026 in Review

Wealth Enhancement Advisory Services sold out of Cardiff Oncology (CRDF) in Q3 2026, closing a stake of 12,095 shares — an estimated $16.1K sold.

Wealth Enhancement Advisory Services first reported a position in CRDF in Q2 2026 and held it in 1 quarter. The position peaked at $16.1K in Q2 2026. 75 funds tracked by Wall St. Rank hold CRDF as of Q3 2026.

  • Wealth Enhancement Advisory Services reported no remaining Cardiff Oncology position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 12,095 Cardiff Oncology shares in Q3 2026, an estimated $16.1K.
  • Wealth Enhancement Advisory Services first reported a position in Cardiff Oncology in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Advisory Services's Cardiff Oncology position peaked at $16.1K in Q2 2026.
  • 75 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.